Altamira Therapeutics to Participate in A.G.P.'s Virtual Biotech and Specialty Pharma Conference
Altamira Therapeutics Ltd. (NASDAQ:CYTO) announced its participation in A.G.P.'s Virtual Biotech and Specialty Pharma Conference on October 13, 2021.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Altamira Therapeutics Ltd. (NASDAQ:CYTO) announced its participation in A.G.P.'s Virtual Biotech and Specialty Pharma Conference on October 13, 2021. The management will engage in virtual one-on-one investor meetings, although no webcast will be available due to the event's format.
Altamira focuses on unmet medical needs, particularly in RNA therapeutics, allergy protection, and inner ear treatments. Their key products include OligoPhore and SemaPhore (preclinical), Bentrio (commercial), and AM-125 (Phase 2) for vertigo, alongside Keyzilen and Sonsuvi (Phase 3) for tinnitus.
Details
News Market Reaction – CYTO
The recorded move for CYTO in the trading session of this news was -9.90%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
HAMILTON, BERMUDA / ACCESSWIRE / October 6, 2021 / Altamira Therapeutics Ltd. (NASDAQ:CYTO) ("Altamira" or the "Company"), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection protection, and inner ear therapeutics, today announced that management will participate in A.G.P.'s Virtual Biotech and Specialty Pharma Conference on October 13, 2021.
The event will consist of one-on-one virtual investor meetings. Due to the format of the event, no webcast will be available.
About Altamira Therapeutics
Altamira Therapeutics is dedicated to developing therapeutics that address important unmet medical needs. The Company is currently active in three areas: the development of RNA therapeutics for extrahepatic therapeutic targets (OligoPhore™ / SemaPhore™ platforms; preclinical), nasal sprays for protection against airborne viruses and allergens (Bentrio™; commercial) for the treatment of vertigo (AM-125; Phase 2), and the development of therapeutics for intratympanic treatment of tinnitus or hearing loss (Keyzilen® and Sonsuvi®; Phase 3). The Company was founded in 2003 and is headquartered in Hamilton, Bermuda with its main operations in Basel, Switzerland. The shares of Altamira Therapeutics Ltd. trade on the NASDAQ Capital Market under the symbol "CYTO".
Investor contact:
Stephen Kilmer
646.274.3580
sjk@altamiratherapeutics.com
SOURCE: Altamira Therapeutics
View source version on accesswire.com:
https://www.accesswire.com/666973/Altamira-Therapeutics-to-Participate-in-AGPs-Virtual-Biotech-and-Specialty-Pharma-Conference
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.